Case report: Bevacizumab-induced cerebrovascular events: a case series report and literature review
In clinical use, bevacizumab has improved the overall survival (OS) and progression-free survival (PFS) of malignant solid tumors, and the safe use of bevacizumab has gradually become the mainstream direction of clinical, nursing and pharmaceutical research. Bevacizumab is a humanized anti-VEGF drug...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1395129/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823860984993808384 |
|---|---|
| author | Ke Chen Boyang Jiang Boyang Jiang Huiping Yan Huiping Yan Liu Yang Liu Yang Zheling Chen Zheling Chen |
| author_facet | Ke Chen Boyang Jiang Boyang Jiang Huiping Yan Huiping Yan Liu Yang Liu Yang Zheling Chen Zheling Chen |
| author_sort | Ke Chen |
| collection | DOAJ |
| description | In clinical use, bevacizumab has improved the overall survival (OS) and progression-free survival (PFS) of malignant solid tumors, and the safe use of bevacizumab has gradually become the mainstream direction of clinical, nursing and pharmaceutical research. Bevacizumab is a humanized anti-VEGF drug. By binding to VEGF, it loses the opportunity to activate VEGFR and then plays an anti-angiogenic role. In addition, more and more studies have emphasized the efficacy and safety of bevacizumab in the treatment of brain metastases from solid tumors. Bevacizumab has its advantages in terms of crossing the blood-brain barrier, increasing radiosensitivity, and reducing radiation-induced brain edema. However, VEGF can maintain the normal function of vascular endothelial cells. Blocking the VEGF pathway can lead to endothelial dysfunction, and the anti-VEGF mechanism of bevacizumab will inevitably lead to a series of thrombotic events and bleeding events. This study reported six cases of cerebrovascular accidents, including ischemic stroke and cerebral hemorrhage, after bevacizumab use. At the same time, this study reviewed the related studies of cardiovascular and cerebrovascular accidents caused by bevacizumab, and analyzed the management of such bevacizumab-related adverse events. We put forward our own views on the early identification and long-term management of adverse events, as well as the subsequent reuse of bevacizumab, hoping to provide more basis for the management of clinical bevacizumab application. |
| format | Article |
| id | doaj-art-b82d4ba2df2f468e97b44f180a2f2341 |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-b82d4ba2df2f468e97b44f180a2f23412025-02-10T06:48:59ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-02-011510.3389/fonc.2025.13951291395129Case report: Bevacizumab-induced cerebrovascular events: a case series report and literature reviewKe Chen0Boyang Jiang1Boyang Jiang2Huiping Yan3Huiping Yan4Liu Yang5Liu Yang6Zheling Chen7Zheling Chen8Department of Gastrointestinal Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaCancer Center, Department of Medical Oncology, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, ChinaThe Clinical Medical College, Hangzhou Normal University, Hangzhou, Zhejiang, ChinaCancer Center, Department of Medical Oncology, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, ChinaDepartment of Medical Oncology, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, ChinaCancer Center, Department of Medical Oncology, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, ChinaDepartment of Medical Oncology, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, ChinaCancer Center, Department of Medical Oncology, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, ChinaDepartment of Medical Oncology, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, ChinaIn clinical use, bevacizumab has improved the overall survival (OS) and progression-free survival (PFS) of malignant solid tumors, and the safe use of bevacizumab has gradually become the mainstream direction of clinical, nursing and pharmaceutical research. Bevacizumab is a humanized anti-VEGF drug. By binding to VEGF, it loses the opportunity to activate VEGFR and then plays an anti-angiogenic role. In addition, more and more studies have emphasized the efficacy and safety of bevacizumab in the treatment of brain metastases from solid tumors. Bevacizumab has its advantages in terms of crossing the blood-brain barrier, increasing radiosensitivity, and reducing radiation-induced brain edema. However, VEGF can maintain the normal function of vascular endothelial cells. Blocking the VEGF pathway can lead to endothelial dysfunction, and the anti-VEGF mechanism of bevacizumab will inevitably lead to a series of thrombotic events and bleeding events. This study reported six cases of cerebrovascular accidents, including ischemic stroke and cerebral hemorrhage, after bevacizumab use. At the same time, this study reviewed the related studies of cardiovascular and cerebrovascular accidents caused by bevacizumab, and analyzed the management of such bevacizumab-related adverse events. We put forward our own views on the early identification and long-term management of adverse events, as well as the subsequent reuse of bevacizumab, hoping to provide more basis for the management of clinical bevacizumab application.https://www.frontiersin.org/articles/10.3389/fonc.2025.1395129/fullbevacizumabadverts effectsVEGFcerebrovascular accidentcancercase report |
| spellingShingle | Ke Chen Boyang Jiang Boyang Jiang Huiping Yan Huiping Yan Liu Yang Liu Yang Zheling Chen Zheling Chen Case report: Bevacizumab-induced cerebrovascular events: a case series report and literature review Frontiers in Oncology bevacizumab adverts effects VEGF cerebrovascular accident cancer case report |
| title | Case report: Bevacizumab-induced cerebrovascular events: a case series report and literature review |
| title_full | Case report: Bevacizumab-induced cerebrovascular events: a case series report and literature review |
| title_fullStr | Case report: Bevacizumab-induced cerebrovascular events: a case series report and literature review |
| title_full_unstemmed | Case report: Bevacizumab-induced cerebrovascular events: a case series report and literature review |
| title_short | Case report: Bevacizumab-induced cerebrovascular events: a case series report and literature review |
| title_sort | case report bevacizumab induced cerebrovascular events a case series report and literature review |
| topic | bevacizumab adverts effects VEGF cerebrovascular accident cancer case report |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1395129/full |
| work_keys_str_mv | AT kechen casereportbevacizumabinducedcerebrovasculareventsacaseseriesreportandliteraturereview AT boyangjiang casereportbevacizumabinducedcerebrovasculareventsacaseseriesreportandliteraturereview AT boyangjiang casereportbevacizumabinducedcerebrovasculareventsacaseseriesreportandliteraturereview AT huipingyan casereportbevacizumabinducedcerebrovasculareventsacaseseriesreportandliteraturereview AT huipingyan casereportbevacizumabinducedcerebrovasculareventsacaseseriesreportandliteraturereview AT liuyang casereportbevacizumabinducedcerebrovasculareventsacaseseriesreportandliteraturereview AT liuyang casereportbevacizumabinducedcerebrovasculareventsacaseseriesreportandliteraturereview AT zhelingchen casereportbevacizumabinducedcerebrovasculareventsacaseseriesreportandliteraturereview AT zhelingchen casereportbevacizumabinducedcerebrovasculareventsacaseseriesreportandliteraturereview |